Literature DB >> 2029583

Production of granulocyte-macrophage colony-stimulating factor by large granular lymphocytes stimulated with Candida albicans: role in activation of human neutrophil function.

D K Blanchard1, M B Michelini-Norris, J Y Djeu.   

Abstract

In the present study, culture supernatants from larger granular lymphocytes (LGL) that were activated with Candida albicans antigens were shown to stimulate the ability of neutrophils to inhibit fungal growth. Identification of the activation factors showed that granulocyte-macrophage colony-stimulating factor (GM-CSF), a hematopoietic growth factor, was involved. Human peripheral blood mononuclear cells were fractionated by Percoll density centrifugation and each subpopulation of cells was stimulated with C albicans yeast cells. GM-CSF was produced in those fractions enriched for LGL, but not T lymphocytes or adherent monocytes. Additionally, the phenotype of the GM-CSF-producing cell was found to be CD2+, CD16+, HLA-DR+, and negative for CD4, CD8, and CD15. Kinetic studies demonstrated that GM-CSF appeared in the supernatants within 2 days of culture and continued to be produced up to 7 days. Optimal stimulation of LGL was seen at a ratio of 3 heat-killed C albicans yeast cells per LGL. Thus, LGL play an important role in host defense against this opportunistic pathogen by producing cytokines, including GM-CSF, which in turn activates the fungicidal activity of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029583

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Lymphocyte adhesion to Candida albicans.

Authors:  Christopher B Forsyth; Herbert L Mathews
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production.

Authors:  J W Murphy; A Zhou; S C Wong
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

4.  Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor.

Authors:  T Tanida; F Rao; T Hamada; E Ueta; T Osaki
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans.

Authors:  G Arancia; A Molinari; P Crateri; A Stringaro; C Ramoni; M L Dupuis; M J Gomez; A Torosantucci; A Cassone
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

6.  Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans.

Authors:  C M Ausiello; F Urbani; S Gessani; G C Spagnoli; M J Gomez; A Cassone
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis.

Authors:  F De Bernardis; A Molinari; M Boccanera; A Stringaro; R Robert; J M Senet; G Arancia; A Cassone
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Increased C3 production in human monocytes after stimulation with Candida albicans is suppressed by granulocyte-macrophage colony-stimulating factor.

Authors:  A K Høgåsen; T G Abrahamsen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 9.  Production and function of cytokines in natural and acquired immunity to Candida albicans infection.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Microbiol Rev       Date:  1995-12

Review 10.  Treatment of invasive candidiasis in immunocompromised pediatric patients.

Authors:  Brian T Fisher; Theoklis E Zaoutis
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.